List view / Grid view
In this in-depth Q&A, Mutlu Dogruel, Vice President of AI at Cresset shares his insights surrounding chatbots, retrieval augmented generation and AI hallucinations, to open up new possibilities for innovation in pharmaceutical research.
In this four-part series, Dr Raminderpal Singh discusses the challenges surrounding limited data quality and offers some pragmatic solutions. In this fourth article, he talks to John Conway, Chief Visioneer Officer at 20/15 Visioneers for an expert perspective.
In this Q&A, Dr Alan D. Roth, CEO of Oxford Drug Design, explains how his AI drug discovery company, which develops novel molecules for use in cancer treatments, has completed the first in vivo validation in its potential first-in-class approach against multiple tumours. A 28-day mouse trial showed clear efficacy…
In this Q&A, Dalip Sethi, scientific lead for Terumo Blood and Cell Technologies, Cell Therapy Technologies and Innovation portfolio, discusses the integration of AI into CGT manufacturing processes to enhance operational efficiency and accelerate treatment access. He also elucidates the strategies that are being considered to overcome hurdles when implementing…
The model enables researchers to expand the number of tumours that they can study, increasing their ability to detect novel interactions.
16 September 2024 | By Drug Target Review
The increasing use of AI in the life science field marks a pivotal point in history. Although AI is now an indispensable tool in drug discovery, promising to save vast amounts of time and money, there are still many hurdles scientists encounter. This webinar will explore these challenges and offer…
The expansion of Sino Biological and BioGeometry’s strategic partnership promises to accelerate drug discovery.
In this four-part series, Dr Raminderpal Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this third article, he discusses pragmatic guidelines to help support better data quality.
RENAISSANCE can quantify unknown intracellular metabolic states, including metabolic fluxes.
In this four-part series, Dr Raminderpal Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this second article, he discusses the problems that occur when using data of poor quality.
Researchers have developed a new AI tool which recognises that protein behaviour can vary by cell and by tissue type.
In this four-part series, Dr Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this first article, the key attributes that define data quality and its requirement for data scientists are elucidated.
Drug formulation is a cornerstone of modern medicine, turning raw active ingredients into consumable, effective therapies. This critical phase in drug development ensures that medications are safe, effective, and user-friendly. Here Ningfeng Fiona Li, founder and CEO of VasoDynamics, explores the world of drug formulation from its foundations to exploring…
Researchers utilised AI to identify genes that reprogramme GBM cancer cells into dendritic cells within the tumour.
2 August 2024 | By Eurofins Discovery
In this webinar, we will present how challenging recombinant protein such as GPCRs are produced and characterised and how biophysics participates in GPCRs hit finding and hit confirmation.
